Assistant Professor, Department of Hematology/Oncology
Gastrointestinal Cancer Program
Appendix Cancer, Pancreatic Cancer, Liver, Gall Bladder & Bile Duct Cancer, Neuroendocrine Tumors, Esophageal Cancer, Colorectal Cancer, Stomach (Gastric) Cancer
Gastrointestinal Cancers; Young Adult Oncology
It is an honor to join the oncology team at Fox Chase Cancer Center. During my time as a medical student rotating at Fox Chase and through the experience of my own family, I have witnessed personally the unparalleled compassionate care and clinical excellence Fox Chase provides to patients. After completing my Internal Medicine and Hematology/Oncology training at Vanderbilt University Medical Center, I hoped to return home to the Philadelphia area and have been fortunate enough to continue my career at the institution where my medical training began.
I chose to pursue a career in the treatment and research of gastrointestinal cancers due to the patients that I cared for during my residency and fellowship. Many of the patients I treated were young adults when they developed their disease, and they allowed me to see first-hand the unique psychosocial and emotional struggles young adults with malignancies face, motivating me to pursue a career serving them. My goal is to provide the most novel, cutting-edge treatment to each of my patients in parallel with optimal supportive care to mitigate symptom burden and maximize quality of life. Additionally, I hope to play an integral role in development of clinical trials to expand treatment options for all those with GI malignancies.
Undergraduate Training: University of Maryland, College Park, College Park, Maryland, Bachelor of Science in Biological Sciences, Physiology and Neurobiology Specialization, August 2008 – May 2012
Graduate Education: Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, Doctor of Medicine, August 2013 – May 2017
Vanderbilt University School of Medicine, Nashville, Tennessee, Clinical Trials I Course, Master of Science in Clinical Investigation, October 2021 – November 2021
Residency Training: Vanderbilt University Medical Center, Department of Medicine: Internal Medicine, Nashville, Tennessee, July 2017 – June 2020
Fellowship: Vanderbilt University Medical Center, Department of Medicine: Hematology/Oncology, Nashville, Tennessee, July 2020 – June 2023
Undergraduate: University of Maryland, College Park
Graduate Education: Lewis Katz School of Medicine at Temple University
Fellowship: Vanderbilt University Medical Center
Cann, C. G., Tillman, B. F., Davis, E. J., & Johnson, D. B. (2019). Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma. The Oncologist, 24(11), 1495. PMID: 31213499.
Cann, C., Kopparapu, P., Yan, Y., Muterspaugh, A., Chen, H., Zhao, Z., ... & Iams, W. (2020). Prolonged time to clearance of circulating-tumor DNA from patients with limited-stage small-cell lung cancer is associated with inferior progression-free and overall survival. Clinical Cancer Research (Vol. 26, No. 11, pp. 79-79). American Association for Cancer Research Special Conference on Advances in Liquid Biopsies.
Cann, C., & Ciombor, K. K. (2022). Systemic therapy for gastric cancer: Perioperative strategies and beyond. Journal of Surgical Oncology, 125(7), 1151-1160. PMID: 35230696.
Cann, C. G., Shen, C., LaPelusa, M. B., Agarwal, R., Cardin, D. B., & Eng, C. (2022). Supportive care (SC) utilization for patients with locally advanced pancreatic cancer: Review of the National Cancer Data Base (2004-2018). Journal of Clinical Oncology, 40(16_suppl), 4154-4154.
Cann, C. G., LaPelusa, M., Cimino, S., Grieb, B., Ciombor, K. K., Agarwal, R., ... & Eng, C. (2023). Updated analysis: Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 41(4_suppl), 95-95.
Cann, C. G., Lapelusa, M. B., Cimino, S. K., & Eng, C. (2023). Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements. Frontiers in Oncology, 13, 1176950. PMID: 37409250
Patient comments